A study of 189 breast cancer patients found no association between paclitaxel chemotherapy and radiation pneumonitis. No hospitalized cases or deaths from the side effect occurred, regardless of treatment group.
A study suggests chemotherapy, not tamoxifen, is linked to increased stroke risk in women with breast cancer. Chemotherapy remains a key component of treatment despite this finding.
A study found that chemotherapy, but not tamoxifen, is linked to an increased risk of stroke in breast cancer patients. Women who had not completed menopause and those with a history of hypertension or diabetes were more likely to experience a stroke. The researchers conclude that women can use tamoxifen without concern for stroke risk.
A European study found that shorter chemotherapy courses for children with Wilms' tumour are as effective as traditional treatment, but with reduced side effects and healthcare costs. The two-year survival rate was around 90% in both groups.
A meta-analysis of RCT data found that patients receiving adjuvant chemotherapy had a lower risk of death and recurrence than those not receiving chemotherapy. Women with optimally staged stage I ovarian cancer may have an excellent prognosis without adjuvant chemotherapy.
A study of 128 women found that immediate breast reconstruction after mastectomy did not delay the initiation of postoperative chemotherapy. The overall rate of wound complications was 15.5%, with higher rates in patients who underwent immediate breast reconstruction, but these complications did not affect chemotherapy timing.
A study of 4,522 patients found that 48-53% received less than 85% of recommended chemotherapy doses due to treatment delays or dose reductions. Patients over age 60 had significantly higher risk of under-treatment. The study emphasizes the importance of timely and effective chemotherapy management.
The guideline states that routine adjuvant chemotherapy is not recommended for medically fit, average-risk patients with Stage II colon cancer. Patients who receive adjuvant chemotherapy have a small but significant benefit in survival rates, around 4-5% more chance of survival five years after surgery.
Researchers at Cedars-Sinai Medical Center found that combining an anti-tumor vaccine with chemotherapy significantly extended patient survival to 26 months on average. The treatment, which involves dendritic-cell immunotherapy, was shown to slow tumor growth and increase the effectiveness of chemotherapy.
A randomized clinical trial showed that adjuvant chemotherapy and immunotherapy for colon cancer patients offer no disease-free or overall survival benefits after 10 years. The improvements in 5-year survival rates observed in the past have disappeared over time, suggesting that newer chemotherapy regimens may be more effective.
The American Society of Clinical Oncology (ASCO) has released a new technology assessment recommending against the use of chemotherapy sensitivity and resistance assays. The assessment found limitations in the literature, including small sample sizes and low yield of assays, cast doubt on their effectiveness in determining treatment.
A randomized trial of 605 patients with four or more positive lymph nodes found no difference in 5-year relapse-free survival and overall survival between conventional and high-dose chemotherapy. High-dose chemotherapy was shown to confer extra cost and toxicity without added anticancer benefit.
Scientists have solved the structure of a human protein called AGT, which repairs damaged DNA inside human cells. The protein can inadvertently protect cancer cells from chemotherapy agents, rendering them ineffective.
Researchers developed a new cancer treatment combining radioimmunotherapy with conventional chemotherapy, achieving complete remission in 72% of patients with follicular non-Hodgkin's lymphoma. The approach may improve treatment outcomes by targeting remaining cancer cells after chemotherapy.
A study found that 35% of women with noninvasive breast cancer had baseline cognitive impairment prior to chemotherapy, including deficits in verbal learning and memory. The research challenges previous studies' findings on the frequency of cognitive decline secondary to chemotherapy.
Researchers found that clinicians missed about half of symptoms reported by patients, and patients also missed about half of the symptoms recorded by physicians. The study suggests that new patient reporting tools should be developed for use in chemotherapy clinical trials to improve accuracy.
A Phase III clinical trial of Tarceva and chemotherapy showed no overall benefit in survival or response, but a subgroup analysis found young non-smokers treated with Tarceva survived longer than those using chemotherapy. The study suggests that this class of drug may not function well when combined with chemotherapy.
A study has identified a biomarker that can predict which colon cancer patients are most likely to respond to a specific chemotherapy regimen. The enzyme thymidine phosphorylase (TP) is found in some, but not all, cancers and is believed to activate the drug capecitabine.
Researchers have developed a gene therapy that protects bone marrow cells from chemotherapy's debilitating effects. The study found up to 41% transfer of the protective gene to blood stem cells in patients with advanced cancer, offering new hope for improved treatments.
In a Phase III trial, over 65% of early-stage HER-2 positive breast cancer patients achieved a complete response rate when treated with Herceptin and chemotherapy. The results were so striking that the trial was halted early after accruing 42 patients.
Researchers at UC Davis Cancer Center discovered that sequential administration of erlotinib and docetaxel enhances effectiveness in treating non-small cell lung cancer. The study showed that giving docetaxel first, then erlotinib, was more effective than simultaneous or alternative administration.
The FDA-approved Avastin increases patient survival by almost five months when combined with chemotherapy, showing a 10.6-month progression-free survival rate compared to 6.2 months in the control group.
A randomized clinical trial found that regional and systemic adjuvant chemotherapy regimens had similar survival rates for colon cancer patients, with the combination regimen offering no added benefit. The study, published in the Journal of the National Cancer Institute, also showed lower adverse reaction rates for regional therapy.
Dr Yeo's study found that prophylactic lamivudine significantly reduces the incidence of HBV reactivation and hepatitis in breast cancer patients. The drug was effective in reducing the risk of liver damage caused by HBV reactivation during and after chemotherapy.
A widely used anti-nausea drug, dexamethasone, may interfere with cancer chemotherapy. Pretreatment with dexamethasone reduces the ability of paclitaxel and doxorubicin to kill cancer cells by upregulating genes that protect breast cancer cells from cell death.
Researchers found that a combination of surgery and intraperitoneal hyperthermic chemotherapy (IPHC) can increase survival rates for patients with peritoneal carcinomatosis. The procedure, which delivers heated chemotherapy directly to the tumor site, has shown promise in improving quality of life and extending survival.
A study from Duke University Medical Center found that virtual reality interventions significantly reduced symptom distress and fatigue in breast cancer patients during chemotherapy. Participants reported a decrease in nausea and vomiting, as well as improved mental state, after using the technology.
A meta-analysis of genetic counseling for breast, ovarian, and colorectal cancer found improved knowledge of cancer genetics, but no impact on perceived risk. A gene mutation affecting folate metabolism alters the sensitivity of colon and breast cancer cells to chemotherapy drugs.
A new study suggests that premenopausal women with ER-negative breast cancer may benefit from adjuvant chemotherapy alone or followed by goserelin, while those with ER-positive tumors show no significant difference in outcomes. The findings support the idea of ovarian suppression as a treatment alternative for some premenopausal women.
A nationwide survey found that 56% of women with early stage breast cancer received less than 85% of their prescribed chemotherapy dose intensity. Treatment delays and dose reductions were common due to neutropenia, a shortage of infection-fighting white blood cells.
A study of 362 patients has shown that breast conservation after neoadjuvant chemotherapy is a safe and effective alternative to mastectomy for many patients. The key to success lies in careful patient selection and coordination among treatment specialists, with low rates of local-regional recurrence reported.
A new study found that chemotherapy and radiation together is more effective than sequential treatment in preserving the voice box, with 88% of patients still having their voice after two years. Overall survival rates were similar for all three treatment options.
A new study found that adding aprepitant to standard treatment for nausea and vomiting can effectively prevent these symptoms following chemotherapy. The medication reduced nausea and vomiting both on the day of chemotherapy administration and in the days that followed.
A new study found that adjuvant chemotherapy did not improve survival rates for patients with surgically removed non-small-cell lung cancer. Additionally, a study on selenium supplementation revealed that it may increase the risk of squamous cell carcinoma and total nonmelanoma skin cancer in individuals at high risk.
A large-scale clinical study by Nordic collaboration has provided new insights into the effects of chemotherapy in colorectal cancer. The analysis demonstrated that among 2,223 patients, those given chemotherapy as part of routine care had a five-year survival rate of 56%, compared to 49% for those treated by surgery alone.
A meta-analysis of 14 trials showed no survival benefit with chemotherapy, but adjuvant radiotherapy resulted in a 7% higher mortality rate. Professor Thatcher suggests further research is needed to confirm the result.
A new study reveals that patients who received neoadjuvant chemotherapy lived an average of 31 months longer than those treated with surgery alone. The combination therapy showed a 66% greater chance of surviving bladder cancer.
A study found that delaying chemotherapy until disease progression was equivalent to immediate treatment in overall survival and specific survival rates. Patients aged over 70 had a higher chance of not requiring chemotherapy after 10 years.
Researchers found that a paclitaxel combination improved median and long-term survival rates for patients with early-stage SCLC. The treatment also reduced side effects compared to standard chemotherapy.
A Canadian-led study found that about 83% of colon cancer patients benefit from traditional chemotherapy, while nearly 17% do not. Further research is needed to provide alternative treatments for those who don't respond to standard therapy.
A recent study found that high-dose chemotherapy followed by autologous stem cell transplant did not significantly increase survival rates for women with early stage breast cancer. The study, which included 511 patients, showed a higher number of relapses in the treatment group but also nine deaths due to transplantation complications....
Women treated with radiation therapy and chemotherapy had a 61% lower risk of developing breast cancer compared to those who received only radiation. The authors suggest that ovarian hormones play a role in promoting tumor growth after radiation, which may explain the increased breast cancer risk in young women exposed to radiation.
Researchers at St. Jude Children's Hospital have successfully treated four pediatric patients with retinoblastoma using a combination of chemotherapy, radiation therapy, and stem-cell transplantation. The study shows promising results, with two out of four patients surviving for over six years without disease recurrence.
Contrast-enhanced MRI is a reliable method to measure blood flow to tumors, allowing for accurate assessment of chemotherapy response and tumor viability. The study found that patients who responded to treatment had significant decreases in angiogenesis, while non-responders showed increases.
A study by Dr. Pio and colleagues found that FLT-PET imaging outperforms FDG-PET in predicting tumor response to chemotherapy in breast cancer patients. The researchers compared the two imaging modalities in 11 newly diagnosed patients, taking scans before treatment began, after the first dose, and following the final cycle.
A study of 800 women with relapsing ovarian cancer found that combination chemotherapy showed a modest survival benefit compared to platinum-based chemotherapy alone. Women assigned combination therapy survived for an average of five months more than those given platinum therapy.
Chemoembolization is the treatment of choice for widespread or diffuse tumors, enabling patients with primary liver cancer to live longer and maintain a quality of life. The procedure uses oil droplets to transport chemotherapy agents directly to the tumor, reducing toxicity and improving outcomes.
Two studies found that paclitaxel-based chemotherapy regimens and mini-transplants can help preserve ovarian function in younger patients. The paclitaxel regimen improved a woman's chance of regaining her ovarian function, while mini-transplants showed better results in preserving ovaries compared to high-dose chemo.
A new study found that chemotherapy and radiotherapy together reduce surgery and removal of the voice box due to cancer recurrence. The combination treatment was associated with a significantly lower rate of surgeries compared to standard therapy or radiotherapy alone.
Researchers found that gefitinib can slow lung cancer tumor recurrence when used as maintenance therapy following chemotherapy. The study suggests that gefitinib may keep cancer cells dormant for a period of time.
Researchers at Stanford have shown positive results with a new chemotherapy combination, Iressa and FOLFOX, in treating colon cancer. The treatment has been effective in shrinking tumors by up to 75% in patients who had never received chemotherapy before.
A new DNA array technology test has identified differences in gene patterns that predict which breast cancer patients will respond to chemotherapy. The study, led by Dr. Jenny Chang at Baylor College of Medicine, found that 88% of genes were correctly classified, allowing for personalized treatment strategies.
Bevacizumab significantly extends survival time for metastatic colorectal cancer patients by shrinking tumors and inhibiting tumor growth. The study showed a median survival increase of five months compared to standard chemotherapy alone, with significant delays in cancer progression.
Researchers at the University of Texas M. D. Anderson Cancer Center have developed a gene screen that can accurately predict which chemotherapy regimens will be effective for patients with newly diagnosed breast cancer. The test is 75% accurate in forecasting complete eradication of cancer, eliminating the need for trial and error.
A new radiotherapy strategy, hyperfractionated accelerated radiotherapy (HART), has been shown to improve survival rates for lung cancer patients. In a phase III multi-site study, chemotherapy followed by HART resulted in a median survival of 21 months, compared to 12 months with standard radiation therapy.
A Phase II study shows that administering ADVEXIN, a p53 drug, directly to tumors can improve the results of neoadjuvant chemotherapy in locally advanced breast cancer. The treatment resulted in dramatic tumor shrinkage and minimal residual tumor cells.
Researchers at McGill University discovered a genetic mutation, MTHFR variant, that predicts better response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer patients. The study found 26 out of 43 patients with the variant responded well to chemotherapy.
Researchers found that ovarian cancer cells produce collagen VI, which remodels their environment to make them more resistant to chemotherapy. This could lead to new therapeutic interventions to overcome chemotherapy resistance and improve survival rates for women with ovarian cancer.
A new study found that strengthening upper leg muscles does not protect against knee osteoarthritis and may even worsen it in people with certain knee conditions. Researchers also discovered that one-third of cancer patients who died received chemotherapy in their last six months of life.
A Phase III randomized trial found that a combination of vinorelbine and gemcitabine did not improve overall and progression-free survival in elderly NSCLC patients. However, the study suggests that certain chemotherapy combinations, particularly cisplatin-based regimens, may be more effective than single-agent therapy. The results als...